These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38389126)

  • 1. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
    Chen M; Yin B; Liu Y; Li M; Shen S; Wu J; Li W; Fan J
    Cell Cycle; 2024 Jan; 23(1):56-69. PubMed ID: 38389126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
    Gustafsson A; Fritz HKM; Dahlbäck B
    Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
    Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
    Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
    Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
    J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
    Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
    Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib activates Axl signaling in renal cell cancer.
    van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
    Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
    Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
    Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.
    Gustafsson A; Boström AK; Ljungberg B; Axelson H; Dahlbäck B
    PLoS One; 2009 Oct; 4(10):e7575. PubMed ID: 19888345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
    Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
    Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
    Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
    Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
    Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
    Qu L; Ding J; Chen C; Wu ZJ; Liu B; Gao Y; Chen W; Liu F; Sun W; Li XF; Wang X; Wang Y; Xu ZY; Gao L; Yang Q; Xu B; Li YM; Fang ZY; Xu ZP; Bao Y; Wu DS; Miao X; Sun HY; Sun YH; Wang HY; Wang LH
    Cancer Cell; 2016 May; 29(5):653-668. PubMed ID: 27117758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis.
    Wang Y; Peng M; Zhong Y; Xiong W; Zhu L; Jin X
    Oncogene; 2023 Mar; 42(13):952-966. PubMed ID: 36732658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.
    Landolt L; Eikrem Ø; Strauss P; Scherer A; Lovett DH; Beisland C; Finne K; Osman T; Ibrahim MM; Gausdal G; Ahmed L; Lorens JB; Thiery JP; Tan TZ; Sekulic M; Marti HP
    Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28596300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.
    Zucca LE; Morini Matushita MA; da Silva Oliveira RJ; Scapulatempo-Neto C; de Lima MA; Ribeiro GG; Viana CR; Cárcano FM; Reis RM
    Urol Oncol; 2018 Jan; 36(1):11.e13-11.e21. PubMed ID: 28986088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
    Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
    Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
    Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
    J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.